XML 49 R37.htm IDEA: XBRL DOCUMENT
v3.22.0.1

Goodwill and Intangible Assets (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract] |
Goodwill | The following table summarizes the changes in the carrying amount of Goodwill:
|  | December 31,
(in millions) |  | 2021 |  | 2020
Beginning balance |  | $ | 8,108 |  |  | $ | 4,117 |
Goodwill resulting from acquisitions |  | 226 |  |  | 3,991 |
Measurement period adjustments |  | (2) |  |  | — |
Ending balance |  | $ | 8,332 |  |  | $ | 8,108 |
Indefinite-Lived Intangible Assets | The following table summarizes our Intangible assets, net:
|  | December 31, 2021 |  | December 31, 2020
(in millions) |  | Gross Carrying Amount |  | Accumulated Amortization |  | Foreign Currency Translation Adjustment |  | Net Carrying Amount |  | Gross Carrying Amount |  | Accumulated Amortization |  | Foreign Currency Translation Adjustment |  | Net Carrying Amount
Finite-lived assets |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Intangible asset - sofosbuvir |  | $ | 10,720 |  |  | $ | (5,651) |  |  | $ | — |  |  | $ | 5,069 |  |  | $ | 10,720 |  |  | $ | (4,952) |  |  | $ | — |  |  | $ | 5,768 |
Intangible asset - axicabtagene ciloleucel(1) |  | 7,110 |  |  | (1,501) |  |  | — |  |  | 5,609 |  |  | 6,200 |  |  | (1,105) |  |  | — |  |  | 5,095 |
Intangible asset - Trodelvy(2) |  | 5,630 |  |  | (507) |  |  | — |  |  | 5,123 |  |  | 4,600 |  |  | (63) |  |  | — |  |  | 4,537 |
Intangible asset - Hepcludex |  | 845 |  |  | (72) |  |  | — |  |  | 773 |  |  | — |  |  | — |  |  | — |  |  | — |
Other(3) |  | 1,610 |  |  | (650) |  |  | 1 |  |  | 961 |  |  | 1,377 |  |  | (540) |  |  | (1) |  |  | 836 |
Total finite-lived assets |  | 25,915 |  |  | (8,381) |  |  | 1 |  |  | 17,535 |  |  | 22,897 |  |  | (6,660) |  |  | (1) |  |  | 16,236 |
Indefinite-lived assets - IPR&D(4) |  | 15,920 |  |  | — |  |  | — |  |  | 15,920 |  |  | 16,890 |  |  | — |  |  | — |  |  | 16,890 |
Total intangible assets |  | $ | 41,835 |  |  | $ | (8,381) |  |  | $ | 1 |  |  | $ | 33,455 |  |  | $ | 39,787 |  |  | $ | (6,660) |  |  | $ | (1) |  |  | $ | 33,126 |
________________________________ (1) Gross carrying amount as of December 31, 2021 includes $910 million reclassified in the first quarter of 2021 from indefinite-lived assets - IPR&D following the March 2021 FDA approval of Yescarta for the treatment of adult patients with relapsed or refractory follicular lymphoma. (2) Gross carrying amount as of December 31, 2021 includes Trodelvy for metastatic TNBC and Trodelvy for use in adult patients with locally advanced or metastatic UC. The amount related to UC of $1.0 billion was reclassified to finite-lived assets from indefinite-lived assets - IPR&D upon the accelerated approval by FDA in April 2021. (3) In October 2021, FDA granted approval of Tecartus for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Accordingly, the related amount of $200 million was reclassified to finite-lived assets in the fourth quarter of 2021. (4) Gross carrying amount as of December 31, 2021 includes IPR&D from our 2021 acquisition of MYR and remaining IPR&D from our 2020 acquisition of Immunomedics. Gross carrying amount as of December 31, 2020 includes IPR&D from our 2020 acquisition of Immunomedics and remaining IPR&D from our 2017 acquisition of Kite.
Finite-Lived Intangible Assets | The following table summarizes our Intangible assets, net:
|  | December 31, 2021 |  | December 31, 2020
(in millions) |  | Gross Carrying Amount |  | Accumulated Amortization |  | Foreign Currency Translation Adjustment |  | Net Carrying Amount |  | Gross Carrying Amount |  | Accumulated Amortization |  | Foreign Currency Translation Adjustment |  | Net Carrying Amount
Finite-lived assets |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Intangible asset - sofosbuvir |  | $ | 10,720 |  |  | $ | (5,651) |  |  | $ | — |  |  | $ | 5,069 |  |  | $ | 10,720 |  |  | $ | (4,952) |  |  | $ | — |  |  | $ | 5,768 |
Intangible asset - axicabtagene ciloleucel(1) |  | 7,110 |  |  | (1,501) |  |  | — |  |  | 5,609 |  |  | 6,200 |  |  | (1,105) |  |  | — |  |  | 5,095 |
Intangible asset - Trodelvy(2) |  | 5,630 |  |  | (507) |  |  | — |  |  | 5,123 |  |  | 4,600 |  |  | (63) |  |  | — |  |  | 4,537 |
Intangible asset - Hepcludex |  | 845 |  |  | (72) |  |  | — |  |  | 773 |  |  | — |  |  | — |  |  | — |  |  | — |
Other(3) |  | 1,610 |  |  | (650) |  |  | 1 |  |  | 961 |  |  | 1,377 |  |  | (540) |  |  | (1) |  |  | 836 |
Total finite-lived assets |  | 25,915 |  |  | (8,381) |  |  | 1 |  |  | 17,535 |  |  | 22,897 |  |  | (6,660) |  |  | (1) |  |  | 16,236 |
Indefinite-lived assets - IPR&D(4) |  | 15,920 |  |  | — |  |  | — |  |  | 15,920 |  |  | 16,890 |  |  | — |  |  | — |  |  | 16,890 |
Total intangible assets |  | $ | 41,835 |  |  | $ | (8,381) |  |  | $ | 1 |  |  | $ | 33,455 |  |  | $ | 39,787 |  |  | $ | (6,660) |  |  | $ | (1) |  |  | $ | 33,126 |
________________________________ (1) Gross carrying amount as of December 31, 2021 includes $910 million reclassified in the first quarter of 2021 from indefinite-lived assets - IPR&D following the March 2021 FDA approval of Yescarta for the treatment of adult patients with relapsed or refractory follicular lymphoma. (2) Gross carrying amount as of December 31, 2021 includes Trodelvy for metastatic TNBC and Trodelvy for use in adult patients with locally advanced or metastatic UC. The amount related to UC of $1.0 billion was reclassified to finite-lived assets from indefinite-lived assets - IPR&D upon the accelerated approval by FDA in April 2021. (3) In October 2021, FDA granted approval of Tecartus for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Accordingly, the related amount of $200 million was reclassified to finite-lived assets in the fourth quarter of 2021. (4) Gross carrying amount as of December 31, 2021 includes IPR&D from our 2021 acquisition of MYR and remaining IPR&D from our 2020 acquisition of Immunomedics. Gross carrying amount as of December 31, 2020 includes IPR&D from our 2020 acquisition of Immunomedics and remaining IPR&D from our 2017 acquisition of Kite.
Estimated Future Amortization Expense of Finite-Lived Intangible Assets | The following table summarizes the estimated future amortization expense associated with our finite-lived intangible assets as of December 31, 2021:
(in millions) |  | Amount
2022 |  | $ | 1,778 |
2023 |  | 1,778 |
2024 |  | 1,778 |
2025 |  | 1,773 |
2026 |  | 1,765 |
Thereafter |  | 8,663 |
Total |  | $ | 17,535 |

X
- References No definition available. + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275 + Details
Name: | us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267 + Details
Name: | us-gaap_ScheduleOfGoodwillTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 3 -Subparagraph (b),(d) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275 + Details
Name: | us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275 + Details
Name: | us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration